

**Supplemental Table 3. Patient characteristics at baseline TRT and TIL cohort.**

		<b>TRT (n=10)</b>	<b>TIL (n=24)</b>	<b>p value<sup>1</sup></b>
<b>Age mean (min-max)</b>		49.7 (33-71)	53.1 (36-77)	0.39
<b>Gender, n (%)</b>	Male	8 (80)	18 (75)	0.75
	Female	2 (20)	6 (25)	
<b>LDH mean (min-max)</b>		281.0 (144-894)	318.9 (136-973)	0.63
<b>LDH level, n (%)</b>	< 250	7 (70)	11 (45.8)	
	250-500	2 (20)	11 (45.8)	
	> 500	1 (10)	2 (8.3)	
<b>WHO, n (%)</b>	0	5 (50)	15 (62.5)	
	1	3 (30)	8 (33.3)	
	2	0 (0)	1 (4.2)	
	Missing	2 (20)	0 (0)	
<b>Brain metastasis (confirmed), n (%)</b>		5 (50)	7 (29.2)	0.25
<b>Pre-treatment, n (%)</b>	BRAF <sup>i</sup> /MEK <sup>i</sup>	1 (10)	13 (54.2)	<b>0.02</b>
	anti-PD1/ anti-CTLA4	0 (0)	20 (83.3)	<b>&lt;0.001</b>
<b>Prior lines of systemic therapies, n (%)</b>	0-2	10 (100)	12 (50)	<b>0.005</b>
	≥ 3	0 (0)	12 (50)	

<sup>1</sup> Statistically significant p values are indicated in bold